98%
921
2 minutes
20
Aims: To evaluate the psychometric properties of the Adelphi Adherence Questionnaire (ADAQ©) as an adherence measure in a diverse type 2 diabetes mellitus (T2DM) population in routine clinical practice.
Materials And Methods: Data were drawn from the Adelphi T2DM Disease Specific Programme™, a survey of physicians and adults with T2DM consulting in the United States, February-May 2021. Participants completed the ADAQ and single questions on medication satisfaction and convenience. Latent variable modelling (exploratory/confirmatory factor analyses, item response theory, Mokken scaling and bifactor analyses) assessed ADAQ dimensionality and composite scoring. Differential item functioning (DIF) analyses were conducted between participants taking injectable and non-injectable therapies, and with <3 or ≥3 long-term conditions. Correlational analyses with physician-reported adherence and compliance, and patient-reported treatment satisfaction, convenience and side-effects assessed construct validity. ADAQ scores by sociodemographic and clinical factors were also described.
Results: Overall, 1287 people with T2DM were included in this analysis (mean age 56.7 years [standard deviation: 12.8], 54.5% [n = 702] male). Latent variable modelling indicated a unidimensional reflective model fit, with a bifactor model confirming an 11-question essentially unidimensional composite score. Negligible DIF was found between groups. Cronbach's alpha and McDonald's omega were both ≥0.90. Moderate correlations with physician-reported adherence and compliance, and patient-reported medication convenience and satisfaction support construct validity.
Conclusions: The ADAQ shows strong construct validity and high internal consistency reliability within a heterogenous T2DM population with negligible DIF between sub-groups. Future work should focus on test-retest reliability and detecting change over time.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12326892 | PMC |
http://dx.doi.org/10.1111/dom.16551 | DOI Listing |
Clin Transplant
August 2025
Health Management Medicine Center, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Background: Immunosuppressive medication (IM) adherence, a dynamic and time-dependent behavior, is typically suboptimal among kidney transplant recipients (KTRs) and severely impacts their prognosis. Longitudinal data regarding the temporal trajectories of medication adherence are important for devising targeted intervention strategies.
Objective: To identify the trajectories of IM adherence in KTRs over the 2 years post transplantation.
J Viral Hepat
September 2025
GSK, Collegeville, Pennsylvania, USA.
Nucleos(t)ide analogue (NA) therapy is the current standard of care for chronic hepatitis B (CHB) virus infection but rarely achieves functional cure, necessitating long-term therapy, which often leads to nonadherence and increased treatment burden. This retrospective cohort study was designed to describe treatment discontinuation and adherence to second-generation NAs among patients with CHB in Japan. We used the Japanese Medical Data Center Claims Database (JMDC Inc.
View Article and Find Full Text PDFJHLT Open
August 2025
Ahmanson/UCLA Adult Congenital Heart Disease Center and UCLA Mattel Children's Hospital, University of California Los Angeles, Los Angeles, CA.
Background: Limited data exist on the use of drugs in patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD). Therefore, we evaluated their real-world patient journey, including symptomatology, diagnostic pathway, treatment patterns, and guideline adherence.
Methods: Data were drawn from the Adelphi Real World pulmonary hypertension congenital heart disease Disease Specific Programme (DSP), a cross-sectional survey of clinicians and patients with PAH-CHD or Fontan circulation associated with elevated pulmonary vascular resistance (PVR).
BMC Cancer
July 2025
Guy's and St Thomas' NHS Foundation Trust, London, UK.
Background: Cyclin-dependent kinase 4/6 inhibitors combined with endocrine therapy are now standard of care in the first- or second-line settings for hormone receptor positive (HR+), human epidermal growth factor 2 negative (HER2-) patients with advanced / metastatic breast cancer (ABC/MBC). Abemaciclib was first authorised in the United Kingdom (UK) in 2018 via patient access schemes before approval for routine use. This study assessed the treatment patterns and outcomes of abemaciclib in combination with endocrine therapy in a real-world setting.
View Article and Find Full Text PDFHeart Fail Rev
July 2025
Erika Feller, MD, Department of Cardiology, MedStar Baltimore, Baltimore, MD, USA.
This review comprehensively examines the complex influence of demographic factors on heart failure with preserved ejection fraction (HFpEF), an increasingly common clinical syndrome. We examine the impact of age, sex, race/ethnicity, and socioeconomic status on HFpEF, investigating how these factors contribute to disparities in prevalence, risk profiles, diagnostic challenges, treatment responses, and clinical outcomes. Key findings highlight the significant role of age, with HFpEF incidence rising with advancing age advances and distinct pathophysiological mechanisms noted across age groups.
View Article and Find Full Text PDF